• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Henry Schein makes $400M increase to share repurchase plan

Henry Schein makes $400M increase to share repurchase plan

August 18, 2022 By Sean Whooley

Henry Schein logo Henry Schein (Nasdaq:HSIC) announced today that its board of directors authorized a repurchase plan worth up to $400 million.

Melville, New York–based Henry Schein’s authorization of the repurchase of up to $400 million in shares of the company’s common stock adds to a $400 million repurchase program announced in May 2021. That plan from more than a year ago was fully executed.

According to a news release, Henry Schein had approximately 136 million shares outstanding as of yesterday, Aug. 17, 2022.

The new share repurchase plan authorization represents approximately 3.9% of the shares outstanding at the current stock price. Purchases may be made from time to time in the open market, or through negotiated transactions, the company said.

“This new share repurchase authorization reflects our team’s commitment to delivering on our strategic priorities and creating sustainable value by investing in our business for growth,” said Ronald N. South, SVP and CFO of Henry Schein. “We are acutely focused on deploying capital to drive long-term value and executing on our balanced capital allocation strategy, which includes investments to support organic growth, strategic acquisitions, and share repurchases.”

The news comes more than two weeks after Henry Schain reported second-quarter sales that missed the Wall Street consensus forecast amid declining COVID-19 test demand and foreign exchange headwinds. The company also reduced its expected revenue growth for the year.

CEO Stanley M. Bergman said at the time: “While we are maintaining our full-year 2022 diluted EPS guidance range… we are adjusting our expectations for full-year sales growth to reflect changes, including a continued strengthening of the U.S. dollar and declining demand for COVID-19 test kits.”

Filed Under: Business/Financial News, Dental, Funding Roundup, Wall Street Beat Tagged With: Henry Schein

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy